Prognostic significance of serum lactate dehydrogenase in osteosarcoma of the extremity: Experience at Rizzoli on 1421 patients treated over the last 30 years

Tumori

Volumn 90, Issue 5, 2004, Pages 478-484

  Bacci, Gaetano ^a   Longhi, Alessandra ^a   Ferrari, Stefano ^a   Briccoli, Antonio ^a   Donati, Davide ^a   De Paolis, Massimiliano ^a   Versari, Michela ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Osteosarcoma; Prognosis; Serum lactate dehydrogenase

Indexed keywords

LACTATE DEHYDROGENASE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; EVALUATION; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; ITALY; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OSTEOSARCOMA; PROGNOSIS; RELAPSE;

EID: 9344248363     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160409000507     Document Type: Article

References (35)

1. Mirra JM: Bone tumors, Lea & Febiger, Philadelphia, pp 255-349, London, 1989.
2. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG: Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer, 43: 2163-2177, 1979.
3. Jaffe N, Robertson R, Takue Y, Cangir A, Wallace S, Carrasco H, Eftekhari F, Ayala A, Wang A: Control of primary osteosarcoma with chemotherapy. Cancer, 56: 461-466, 1985.
4. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfurst C, Berger J, Ritter J, Jurgens H, Gerein V: Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol, 6: 329-337, 1988.
5. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremities. N Eng J Med, 314: 1600-1606, 1986.
6. Sater G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP: Treatment of osteosarcoma of the extremity with T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol, 9: 1766-1775, 1991.
7. Benjamin RS, Chawla SP, Carrasco CH, Raymond AK, Murray JA, Armen T, Patel S, Wallace S, Ayala A, Papadopoulos NE: Preoperative chemotherapy for osteosarcoma with intravenous doxorubicin and intra-arterial cis-platinum. Ann Oncol, 2: 3-6, 1992.
8. Provisor AJ, Ettinger LJ, Nachman JB Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol, 15: 76-84, 1997.
9. Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, Graf N, Heise U, Jurgens H, Kotz R, Salzer-Kuntschik M, Weinel P, Werner M, Winkler K: Long-term results of the cooperative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol, 9: 893-899, 1998.
10. Bielack SS, Kempf-Bielack B, Delling G: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocol. J Clin Oncol, 20: 776-790, 2002.
11. Dispersio L, Kyriazis AP, Michael JG: Monitoring the therapy of human tumor xenografts in nude mice by the use of lactate dehydrogenase. J Natl Cancer Int, 62: 375-379, 1979.
12. Nakamura T, Kitagawat A: Anticancer drug screen test with LDH in nude mouse bearing bone and soft part sarcoma. Cancer, 56: 1122-1116, 1985
13. Bierman HR, Hill BR, Reimbrardt L: Correlation of lactic dehydrogenase activity with the clinical status of patients with cancer, lymphoma and leukemia. Cancer Res, 17: 660-667, 1957.
14. Lippen MC, Javadpour N: Lactic dehydrogenase in the monitoring and prognosis of testicular cancer. Cancer, 46: 352-354, 1981.
15. Brereton DH, Simon R, Pomeroy TC: Pretreatment serum lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma. Ann Intern Med, 83: 352-354, 1975.
16. Bacci G, Ferrari S, Longhi A, Rimondini S, Versari M, Zanone A, Forni C: Prognostic significance of serum LDH in Ewing's sarcoma of bone. Oncol Rep, 6: 807-811, 1999.
17. Bacci G, Ferrari S, Sangiorgi L, Picci P, Casadei R, Orlandi M, Intorno D, Battistini A, Zanone A: Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. J Chemother, 6: 204-210, 1994.
18. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol, 10: 5-15, 1992.
19. Meyers PA, Heller G, Vlamis V: Osteosarcoma of the extremities: chemotherapy experience at the Memorial Sloan-Kettering. In: Osteosarcoma in adolescents and young adults, Bennett HG (Ed), pp 309-311, Kluwer Academic, Boston, 1993.
20. Link MP: The multi-institutional Osteosarcoma, study: an update. In: Osteosarcoma in adolescents and young adults. Bennett HG (Ed), pp 107-112, Kluwer Academic, Boston, 1993.
21. Enneking WF, Spanier S, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop, 153: 106-120, 1980.
22. Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, Bertoni F, Guerra A, Capanna R, Albisinni U: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer, 56: 1515-1521, 1985.
23. Campanacci M, Bacci G, Bertoni F, Picci P, Minutillo A, Franceschi C: The treatment of Osteosarcoma of the extremities: twenty years experience at the Istituto Ortopedico Rizzoli. Cancer, 48: 1569-1581, 1981.
24. Bacci G, Gherlinzoni F, Picci P, Van Horn JR, Jaffe N, Guerra A, Ruggieri P, Biagini R, Capanna R, Toni A: Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for Osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol, 22: 1337-1345, 1986.
25. Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, Brach Del Prever A, Mancini A, Gherlinzoni F, Padovani G: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer, 65: 2539-2553, 1990.
26. Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, Brach del Prever A, Gherlinzoni F, Mercuri M, Monti C: Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer, 72: 3227-3238, 1993.
27. Bacci G, Picci P, Ferrari S, Casadei R, Brach Del Prever A, Tienghi A, Mancini A: Influence of adriamycin dose in the outcome of patients with osteosarcoma treated with multidrug neoadjuvant chemotherapy: results of two sequential studies. J Chemother, 5: 237-246, 1993.
28. Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R, Donati D, Lari S, Forni C, DePaolis M: Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol. Eur J Cancer, 37: 2030-2039, 2001.
29. Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, Briccoli A, Forni C: High dose ifosfamide in combination with high dose methotrexate, doxorubicin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother, 14: 198-206, 2002.
30. Lorentz K, Klauke R, Schmidt E: Recommendation for the determination of the catalytic concentration of lactate dehydrogenase at 37 degrees C. Standardization Committee of the German Society for Clinical Chemistry, Enzyme Working Group of the German Society for Clinical Chemistry. Eur J Clin Chem Clin Biochem, 31: 897-899, 1993.
31. Davis AM, Bell RS, Goodwin PJ: Prognostic factors in osteosarcoma: a critical review. J Clin Oncol, 12: 423-31, 1994.
32. McKenna RJ, Schwin CP, Soong KJ: Sarcomata of osteogenic series: analysis of 552 cases. J Bone Joint Surg, 48: 126, 1966.
33. Lockshin M, Higgins I: Prognosis in osteogenic sarcoma. Clin Orthop, 58: 85-103, 1968.
34. Thorpe W, Reilly J, Rosemberg S: Prognostic significance of alkaline phosphatase measurement in patients with osteogenic sarcoma receiving chemotherapy. Cancer, 43: 2178-2181, 1979.
35. Bacci G, Longhi A, Ferrari S, Lari S, Manfrini M, Donati D, Forni C, Versari M: Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute. Oncol Rep, 9: 171-175, 2002.